Johnson & Johnson (NYSE: JNJ) is recognized as one of the 12 Best Dividend Paying Stocks to Buy Now, with a market value close to $425 billion. The company saw a 5.8% increase in second-quarter revenue and an 18% rise in earnings compared to the previous year.

Previously, Johnson & Johnson (NYSE: JNJ) had a consumer healthcare division that included popular products like Tylenol and Band-Aid, which was spun off into a separate company called Kenvue in 2023.

Johnson & Johnson (NYSE: JNJ) boasts a diverse portfolio, including immunology treatments like Stelara and Tremfya, cancer drugs like Darzalex and Erleada, and 40 programs in late-stage clinical trials for new drug candidates and approvals for existing treatments.

With a 63-year track record of dividend growth, Johnson & Johnson (NYSE: JNJ) is favored by income investors for its generous dividends. The company currently pays a quarterly dividend of $1.30 per share and has a dividend yield of 2.95% as of September 19.

Read more at Yahoo Finance: Johnson & Johnson’s (JNJ) Dividend Growth Record Strengthens its Role in Dividend Paying Stocks